1. Uruguay Stocks

  2. •

    Finance

  3. •

    Investment banks/Brokers
Biomind Labs Inc

Biomind Labs Inc

NNEO:BMND
0.69
CAD
+0.10
(+16.95%)
-0.03EPS
5.43MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.06
-0.04
-0.02
- -
-0.01
-0.02
Free Cash Flow per Basic Share
-0.03
-0.03
-0.01
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
0.03
- -
-0.02
-0.02
-0.02
-0.02
Tangible Book Value per Share
0.03
- -
-0.02
-0.02
-0.02
-0.02
Basic Weighted Avg Shares
72
75
75
76
78
78
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-3
-1
- -
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
2
- -
-1
-1
-2
-2
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
2
- -
-1
-1
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
78
78
Market Capitalization
10
1
4

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
33.49%
Free Cash Flow
- -
- -
-80.94%
Net Income, GAAP
- -
- -
226.48%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
-0.01
-0.01
2026
- -
-0.01
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Alejandro Antalich
Full Time Employees
5
Sector
Finance
Industry
Investment banks/Brokers
Address
701 West Georgia Street, Suite 515 Pando BC Uruguay V7Y 1C6
IPO Date
Jul 27, 2021
Website
biomindlabs.com
Similar Companies
Robinhood Markets, Inc. (NASDAQ:HOOD)
Coinbase Global, Inc. (NASDAQ:COIN)
BSE Ltd. (NSE:BSE)
Goldman Sachs Group, Inc. (The) (NYSE:GS)
Multi Commodity Exchange of India Limited (NSE:MCX)
National Stock Exchange of India Limited (BSE:NSE)
Business
Biomind Labs Inc. Biomind Labs Inc. (BMNDF), a biotechnology research and development company founded in 2019 and headquartered in Toronto, Canada, with operations in Canelones, Uruguay, focuses on transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for psychiatric and neurological conditions. The company develops a diversified pipeline of fast-acting, controlled-release formulations derived from psychedelic molecules such as N,N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline, targeting specific therapeutic indications including treatment-resistant depression (BMND01 in Phase II), fibromyalgia (BMND02 in evaluation), addictive disorders (BMND03 in pre-clinical), chronic pain (BMND05 in evaluation), morbid obesity (BMND06 in Phase I), major depressive disorder (BMND07 in evaluation), Alzheimer's disease-related depression and anxiety (BMND08 in Phase II), and Parkinson's disease (BMND09 in Phase I); it emphasizes tailored drug delivery, personalized medicine, and sustainable production to address biochemical and neurological disease drivers. Recent developments include the announcement of positive Phase II results for BMND08 in treating depression and anxiety in Alzheimer's patients in March 2024, the unveiling of BMND06 as a novel obesity treatment targeting neurological pathways in July 2024, the revocation of a cease-trade order in November 2025 following the filing of delayed 2024 audited financial statements, and an ongoing robust intellectual property portfolio with 19 patent applications across USPTO, PCT, and EPO channels.